drugset / Trial / NCT00819390

Chloroquine for Reducing Immune Activation in HIV- Infected Individuals

NCT00819390

RandomizedCrossoverQuadruple-blindTreatment

Summary

HIV is characterized by frequent immune system activation. Early in the course of infection the body establishes an immune activation "set point" related to the amount of HIV in the blood stream. This set point affects the rate of CD4 cell loss. Without CD4 cells, or with very low levels of CD4 cells, the body cannot fight off illness. This is known as immunodeficiency. If left untreated HIV can lead to extreme immunodeficiency and AIDS. Evidence suggests that by decreasing the rate of immune system activation, immune deficiency progression could be prevented. The purpose of this study is to learn how well chloroquine can reduce the level of immune activation and to test the safety and tolerance of chloroquine in people infected with HIV.

Timeline

Start
2009-03
Primary completion
2013-02
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Chloroquine Small molecule 250 mg Oral